The Cannabis Spread throughout the Continents and its Therapeutic Use in History.

BACKGROUND: Cannabis sativa L. (C. sativa) is a plant whose use as a therapeutic agent shares its origins with the first Far East's human societies. Cannabis has been used not only for recreational purposes but as food to obtain textile fibers, to produce hemp paper, to treat many physical and mental disorders. AIM: This review aims to provide a complete assessment of the deep knowledge of the cannabis psychoactive effects and medicinal properties in the course of history covering i.) The empirical use of the seeds and the inflorescences to treat many physical ailments by the ancient Oriental physicians' ii.) The current use of cannabis as a therapeutic agent after the discovery of its key psychoactive constituent and the human endogenous endocannabinoid system. METHODS: This study was performed through a detailed analysis of the studies on the historical significance and medical applications of Cannabis sativa by using international scientific databases, historical and medical books, ancient Greek and Chinese manuscripts translations, library and statistical data from government reports and texts from the National Library of Greece (Stavros Niarchos Foundation), from the School of Health Sciences of the National and Kapodistrian University of Athens (Greece). We selected papers and texts focusing on a historical point of view about the medical importance of the plant and its applications for a therapeutic purpose in the past. RESULTS AND CONCLUSION: Through a detailed analysis of the available resources about the origins of C. sativa, we found that its use by ancient civilizations as a source of food and textile fibers dates back over 10,000 years, while its therapeutic applications have been improved over the centuries, from the ancient East medicine of the 2nd and 1st millennium B.C. to the more recent introduction in the Western world after the 1st century A.D. In the 20th and 21st centuries, Cannabis and its derivatives have been considered as a menace and banned throughout the world, but nowadays, they are still the most widely consumed illicit drugs all over the world. Its legalization in some jurisdictions has been accompanied by new lines of research to investigate its possible applications for medical and therapeutic purposes.

Trends in Opioid Misuse among Marijuana Users and Non-Users in the U.S. from 2007-2017.

Prescription-opioid misus e continues to be a significant health concern in the United States. The relationship between marijuana use and prescription-opioid misuse is not clear from the extant literature. This study examined national trends in prescription-opioid misuse among marijuana users and non-users using the 2007-2017 National Survey on Drug Use and Health. Cochran-Armitage tests were used to assess the statistical significance of changes in the yearly prevalence of prescription-opioid misuse and marijuana use. Multivariable logistic regression was used to examine the association between prescription-opioid and marijuana use adjusting for sociodemographic characteristics. From 2007 to 2017, marijuana use increased, while prescription-opioid misuse declined. Larger declines in prescription-opioid misuse were found among marijuana users than non-users. Marijuana ever-use was significantly associated with prescription-opioid misuse. Specifically, marijuana ever-users had higher odds of prescription-opioid misuse (ever-misuse [OR: 3.04; 95% CI, 2.68-3.43]; past-year misuse [OR: 3.44; 95% CI, 3.00-3.94]; and past-month misuse [OR: 4.50; 95% CI, 3.35-6.05]) compared to marijuana never-users. Similar results were found for the association of past-year and past-month marijuana use with prescription-opioid misuse. This study provides data on trends and associations about opioid misuse among marijuana users and non-users in a changing social environment of drug use in the United States. Future research should consider whether there is a causal relationship between marijuana use and prescription opioid misuse.

[A brief history of marijuana in the western world]. / Breve historia sobre la marihuana en Occidente.

Marijuana is a substance with a long and controversial history. At different times in its history, which goes back over 5,000 years, this plant has been used for different purposes, ranging from recreational and leisure to its use in the treatment of several diseases or to offer relief in processes that entail a certain type of malaise, and including its consideration as a means of relaxation and meditation. Although it was supposed that the roots of marijuana lay in Central America, it is now known that this is but an urban legend with little credibility and that its origins can be found recorded in Chinese medical references dating back to the year 2737 BC. Although this plant was not originally from Central America, it has aroused interest around the world, and above all in Mexico. It is in this country where the use of cannabis has gone from applications in textiles and medicine to its free sale, the bans on its use due to political and social pressures, its tolerance and, recently, its decriminalisation for recreational and medicinal use. Unfortunately there are few references on the history of this plant in Mexico, and thus we have considered it interesting to present some data about the generalities of marijuana, a brief history in the world, the development of decriminalisation in North America, its medicinal uses and its course through Mexico to the present day.

TITLE: Breve historia sobre la marihuana en Occidente.La marihuana es una sustancia con una extensa y controvertida historia. A lo largo del tiempo, esta planta, y desde hace mas de 5.000 años, ha sido utilizada para diferentes fines, que van desde el uso ludico y recreativo, pasando por un medio de relajacion y meditacion, hasta su uso en el tratamiento de varias enfermedades o el alivio de procesos vinculados a cierto tipo de malestares. Aunque se supuso que la marihuana tenia su origen en Mesoamerica, ahora se sabe que es solo una leyenda urbana de poca credibilidad y que sus origenes los podemos registrar en referencias medicas chinas datadas alrededor del año 2737 a. de C. Si bien esta planta no tiene un origen mesoamericano, si ha generado interes en el mundo, y sobre todo en Mexico. Es en este pais donde el uso del cannabis ha ido desde intereses textiles y medicinales hasta el consumo ludico, pasando por su venta libre, la prohibicion por presiones politicas y sociales, su tolerancia y, recientemente, su despenalizacion para uso ludico y medicinal. Desgraciadamente existen pocas referencias de la historia de esta planta en Mexico, por lo que ha sido de nuestro interes presentar algunos datos sobre las generalidades de la marihuana, una breve historia en el mundo, el desarrollo de la despenalizacion en Norteamerica, sus usos medicinales y su paso por Mexico hasta nuestros dias.

Posverdad del consumo de cannabis: de regreso a la medicina basada en la evidencia / Post-truth Cannabis use: back to evidence-based medicine

No disponible

Evidence-based policy? The re-medicalization of cannabis and the role of expert committees in the UK, 1972-1982.

BACKGROUND: Cannabis was introduced to the UK as a medical product in the nineteenth century. However, with questions over its safety, efficacy, and possible harms its medical role diminished and by the 1950s it was viewed as a drug of misuse. Nonetheless, scientific and lay knowledge around cannabis expanded from the 1960s and cannabis re-appeared in different therapeutic forms. In re-medicalizing cannabis, science-policy transfer proved important and was enabled by the developing mechanism of expert committees, most notably the Advisory Council on the Misuse of Drugs (ACMD). METHODS: This article draws upon previously unknown archival material on the ACMD held at the National Archives and covers the period 1972-1982. It considers how expert groups were established, their membership, and the evolving discussion over therapeutic cannabis within the broader drug policy debate. RESULTS: Three distinct periods emerged: 1972-1976 with the creation of the Working Group on Cannabis; 1977-1979 when the Working Group focused on potential amendments to the Misuse of Drugs Act and recommended downgrading cannabis from Class B to Class C; 1980-1982 when the Expert Group on the Effects of Cannabis recommended downgrading cannabis and encouraged research into cannabis as a medicine. Sources reveal that driven by drug control imperatives the ACMD stimulated research on cannabis leading to increased research on medical applications. CONCLUSION: Expert advice was critical in the process of re-medicalization. Initially, discourse occurred in the closed expert committees of the ACMD. The drug problem had been framed under the criminal justice system but as the limitations of this were revealed, and there was continuing uncertainty over cannabis' impact, new approaches to cannabis were sought. It was this combination of more relaxed attitudes towards cannabis, research incentives, as well as a developing desire to draw medical needs away from discussion of drug control that was to allow re-medicalization to develop.

Hashish in Morocco and Lebanon: A comparative study.

BACKGROUND: In the 1960s and the 1970s, Morocco and Lebanon became major producers of hashish for export to markets in West and Central Europe, Africa and the Middle East. By using a comparative approach, this paper aims to evaluate changes in production in the traditional areas of cannabis cultivation in the Rif (Morocco) and the Beqaa (Lebanon) and to better understand the role that these countries play in current trends in the global cultivation and consumption of cannabis. METHODS: The comparative approach takes in account the historical and institutionnal context, and the perception of cannabis in those two country. We rely on primary field research done in the Rif (from 2002) and in the Beqaa (from 1995) in the form of interviews and observations with farmers and intermediaries. Acreage and production estimates of hashish for both countries have been triangulated from different sources. RESULTS: Maghreb and Middle East have a long history of consumption, production and marketing of cannabis. Over the past 12 centuries, migration, trade and different spiritual practices and trends have led to the expansion of cannabis markets. This long period is marked by stages and rifts caused by foreign interference, a worldwide prohibition of cannabis at the beginning of the 20th century and increased global demand in the 1960s and the 1970s. Morocco and Lebanon are among the most important producers of hashish to be exported for trade for the last fifty years. The global prohibition of cannabis and the global sustained demand have created opportunities for poor farmers in the Rif and the Beqaa regions to survive and get wealthy. It is difficult to understand the reasons why areas producing cannabis are steadily increasing. If the Rif and the Beqaa share some features (such are marginalized areas of production, repressive legislation, huge international demand, range of comparable tasks and Mediterranean climate suitable for growing cannabis, etc.) then a comparison between the two countries makes it more easy to notice differences in contexts, in local and international markets (Stability in Morocco, instability in Lebanon; traditional market in Morocco, absence of local market in Lebanon, etc.) In Morocco, the stability and specialized skills among Moroccan growers of hashish have enhanced a competitive economy with various production areas, products and qualities, but also prices and strategies due to competition between Moroccan and European producers. Moreover, Morocco produces cannabis for its significant local market. CONCLUSION: As shown by comparing Morocco and Lebanon, allows us to examine their perverse effects caused by a global prohibition. The criminalization of growers has only increased their marginalized situation. The enforced eradication of cannabis has limited the cultivation for a short time but not in any sustainable way (resumption of cannabis cultivation in a time of conflict in Lebanon; replacement of local variety by hybrids in Morocco). The cultural heritage of cannabis and its social functions should not be ignored. In the light of the new global changes in the cannabis cultivation (Import substitution, technical progress in developed countries, etc.), hashish producers in the south countries are likely to face uncertain future.

Getting to grips with the cannabis problem: the evolving contributions and impact of Griffith Edwards.

Griffith Edwards played an important role in cannabis policy debates within government advisory committees in the United Kingdom from the early 1970s until the early 1980s. This has largely been hidden from public knowledge by the confidentiality of these committee discussions. The purpose of this paper is to use Griffith's writings and the results of recent historical scholarship to outline the views he expressed, the reasons he gave for them, and to provide a brief assessment of his contribution to the development of British cannabis policy.

High-performance sport, marijuana, and cannabimimetics.

The prohibition on use of cannabinoids in sporting competitions has been widely debated and continues to be a contentious issue. Information continues to accumulate on the adverse health effects of smoked marijuana and the decrement of performance caused by the use of cannabinoids. The objective of this article is to provide an overview of cannabinoids and cannabimimetics that directly or indirectly impact sport, the rules of sport, and performance of the athlete. This article reviews some of the history of marijuana in Olympic and Collegiate sport, summarizes the guidelines by which a substance is added to the World Anti-Doping Agency Prohibited List, and updates information on the pharmacologic effects of cannabinoids and their mechanism of action. The recently marketed cannabimimetics Spice and K2 are included in the discussion as they activate the same receptors as are activated by THC. The article also provides a view as to why the World Anti-Doping Agency prohibits cannabinoid or cannabimimetic use incompetition and should continue to do so.

Cannabis y Salud Mental / Cannabis and Mental Health

El Cannabis es actualmente la droga ilegal más consumida tanto en Europa como en Estados Unidos. Sus criterios de dependencia están definidos por los principales manuales diagnósticos (DSM-IV y CIE-10) y aunque no ocurre así con el síndrome de abstinencia, éste presenta ciertos síntomas significativos que la investigación comienza a concretar. Si bien no todos los consumidores de esta droga presentan problemas de salud mental, las revisiones de los últimos años apuntan a un mayor riesgo de diversos trastornos mentales entre los usuarios de cannabis. Riesgos que están asociados a la menor edad de inicio del consumo, la mayor frecuencia del mismo o a ciertas predisposiciones personales. La investigación no sólo ha desvelado alteraciones que van del espectro psicótico al afectivo, sino también deterioros cognitivos o su relación con la conducta antisocial, el consumo de otras drogas ilegales o con otros riesgos para la salud. Aunque los factores contaminantes y las dificultades de una evaluación precisa del grado e historia de consumo son un gran obstáculo para los avances en este campo, las investigaciones realizadas en los últimos años han proporcionado resultados concluyentes sobre los posibles riesgos del uso de esta droga. El presente artículo revisa los principales hallazgos científicos y conclusiones sobre la asociación entre el uso de cannabis y la salud mental (AU)

Cannabis is currently the most widely consumed illegal drug in both Europe and the United States. Cannabis dependence criteria are defined by the principal diagnostic manuals (DSM-IV and ICD-10), but not cannabis withdrawal syndrome, although cannabis withdrawal produces certain significant symptoms that are beginning to be typified by research. While not all cannabis users present mental health problems, recent reviews point to a greater risk of various mental disorders in cannabis users. The risks are associated with younger age at first use, greater frequency of use or certain personal predispositions. Research has revealed not only alterations in both the psychotic and affective spectra, but also cognitive deterioration and associations between cannabis use and antisocial behavior, use of other illegal drugs and other health risks. Although contaminating factors and the difficulty of accurately assessing the extent and history of cannabis use represent considerable obstacles to progress in this research field, studies carried out in recent years have contributed conclusive findings on the potential risks of cannabis use. The present article reviews the main scientific findings and conclusions with respect to the association between cannabis use and mental health (AU)

On cannabis, chloral hydrate, and career cycles of psychotropic drugs in medicine.

This article compares the careers of two psychotropic drugs in Western psychiatry, with a focus on the nineteenth century: Cannabis indica and chloral hydrate. They were used by doctors for similar indications, such as mania, delirium tremens, and what we would now call drug dependence. The two show similar career paths consisting of three phases: initial enthusiasm and therapeutic optimism; subsequent negative appraisal; and finally, limited use. These cycles, which we term "Seige cycles," are generally typical of the careers of psychotropic drugs in modern medicine. However, differences in the careers of both drugs are also established. The phases of chloral show relatively higher peaks and lower valleys than those of cannabis. Chloral is the first typically "modern" psychotropic drug; a synthetic, it was introduced in 1869 at a time of growing asylum populations, pharmaceutical interests, and high cultural expectations of scientific medicine. Cannabis indica, introduced in the 1840s, is typically a "premodern" drug steeped in the climate of cultural Romanticism. We conclude that the analytical concept of the Seige cycle is a useful tool for future research into drug careers in medicine.

Cannabis in Papua New Guinea.

Cannabis is the most commonly used illicit drug in Papua New Guinea (PNG). Data on the epidemiology and history of cannabis in PNG are presented. The adverse health consequences of cannabis smoking and treatment options for cannabis dependence are discussed. It is recommended that a range of strategies are urgently required in PNG to prevent adverse physical and mental health consequences associated with cannabis smoking.

A história da maconha no Brasil / The history of marihuana in Brazil

A história da maconha no Brasil tem seu início com a própria descoberta do país. A maconha é uma planta exótica, ou seja, não é natural do Brasil. Foi trazida para cá pelos escravos negros, daí a sua denominação de fumo-de-Angola. O seu uso disseminou-se rapidamente entre os negros escravos e nossos índios, que passaram a cultivá-la. Séculos mais tarde, com a popularização da planta entre intelectuais franceses e médicos ingleses do exército imperial na índia, ela passou a ser considerada em nosso meio um excelente medicamento indicado para muitos males. A demonização da maconha no Brasil iniciou-se na década de 1920 e, na II Conferência Internacional do Opio, em 1924, em Genebra, o delegado brasileiro Dr. Pernambuco afirmou para as delegações de 45 outros países: "a maconha é mais perigosa que o ópio". Apesar das tentativas anteriores, no século XIX e princípios do século XX, a perseguição policial aos usuários de maconha somente se fez constante e enérgica a partir da década de 1930, possivelmente como resultante da decisão da II Conferência Internacional do Opio. O primeiro levantamento domiciliar brasileiro sobre consumo de psicotrópicos, realizado em 2001, mostrou que 6,7 por cento da população consultada já havia experimentado maconha pelo menos uma vez na vida (lifetime use), o que significa dizer que alguns milhões de brasileiros poderiam ser acusados e condenados à prisão por tal ofensa à presente lei. No presente, um projeto de lei foi aprovado no Congresso Nacional propondo a transformação da pena de reclusão por uso/posse de drogas (inclusive maconha) em medidas administrativas.

The present study describes of history of Cannabis sativa L. (marihuana) since the arrival in Brazil in the Portuguese discovers, in 1500. During the following centuries Cannabis cultivation was stimulated by the Portuguese Crown, which included sending seeds to Brazil; the medicinal use of Cannabis was also common, mostly during the second part of 19th century, being the Cigarros índios (Cannabis cigarettes) imported from France, and advertised in Brazilian medical journals up to the first years of the 20th century. The repression against Cannabis use reached proportion only in the 20th century. This probably happened because the Brazilian representatives at the II International Conference on Opium and Coca/Cocaine flatly declared that in Brazil Cannabis was "more dangerous than opium". The condemnation of Cannabis in that Conference was seemingly extended up to the 1961 Single Convention of Narcotic Drugs, United Nations, in which Cannabis was considered a "particularly dangerous drug" and as such was included together with heroine in the Schedule IV of that Convention. Possibly, as a consequence the repression started seriously in the beginning of the 1930 decade; and according to the Brazilian law 6.368/1976, the recreational and medical uses of Cannabis products are prohibited. Such uses are criminal offenses and as such the users may face prison penalties. However a new law is under discussion in the Brazilian Congress. According to it the possession of a certain quantity of marihuana (and other drugs) is no longer a criminal offense and will be subject to administrative sanctions.

Cannabis condemned: the proscription of Indian hemp.

AIMS: To find out how cannabis came to be subject to international narcotics legislation. METHOD: Examination of the records of the 1925 League of Nations' Second Opium Conference, of the 1894 Report of the Indian Hemp Drugs Commission and other contemporary documents. FINDINGS: Although cannabis (Indian hemp) was not on the agenda of the Second Opium Conference, a claim by the Egyptian delegation that it was as dangerous as opium, and should therefore be subject to the same international controls, was supported by several other countries. No formal evidence was produced and conference delegates had not been briefed about cannabis. The only objections came from Britain and other colonial powers. They did not dispute the claim that cannabis was comparable to opium, but they did want to avoid a commitment to eliminating its use in their Asian and African territories.

Uso de los cannabinoides a través de la historia / Cannabinoids use through history

La Cannabis Sativa ha sido utilizada con fines industriales, medicinales y/o recreativos desde la Antigüedad. Sin embargo, la investigación sobre sus principios activos es relativamente reciente. Su uso fue conocido en China hace unos cinco mil años. Fue utilizada para la obtención de fibra y de aceite. Sus propiedades curativas aparecen reflejadas en varios tratados médicos de una notable antigüedad. En la India, formaba parte de algunos rituales religiosos y fue utilizado por sus propiedades curativas, práctica que se ha conservado hasta muy recientemente. También se ha descrito su utilización por los asirios, los escitas o los persas. Existe una controversia sobre si fue conocido por los judíos y los egipcios. Tampoco está muy claro el que su uso, salvo con fines industriales, estuviera muy extendido entre los griegos y los romanos. Al principio de la era cristiana, Plinio “el viejo”, Discorides y Galeno describieron sus posibles aplicaciones médicas. Los árabes lo utilizaron en medicina y a nivel recreativo. Sin embargo, su popularidad no fue la misma en cada uno de los países de cultura islámica, llegando incluso a estar prohibido en situaciones históricas concretas. Durante el siglo XIX, la presencia colonial inglesa en la India y la expedición de Napoleón a Egipto, sirvió para la difusión por Europa, y posteriormente por los Estados Unidos, de las aplicaciones médicas y lúdicas del cannabis. Su uso en la práctica médica fue declinando a lo largo del siglo XX, ante la aparición de otros compuestos con mayor eficacia terapéutica (AU)

Cannabis sativa has been used for industrial, medical and/or recreational purposes since ancient times. Nevertheless, research into its active beginnings is relatively recent. It was known in China some five thousand years ago when it was used to obtain fibre and oil. Its curative properties can be seen in various medical treatises of great age. In India, it formed part of certain religious rites, and was used for its curative properties, a practice which continued until very recently. It use by the Assyrians, the Scythians and the Persians has also been described. There is debate on whether or not it was known to the Jews and the Ancient Egyptians. Nor is it very clear if, apart from its use for industrial purposes, it was very widespread among the Greeks and the Romans. At the beginning of the Christian Era, Pliny the Elder, Discorides and Galen described its possible medical applications. The Arabs used it medicinally and recreationally although its popularity was not the same in each of the Islamic countries, and it was even prohibited in certain specific circumstances throughout history. During the 19th century, the British colonial presence in India and Napoleon’s expedition to Egypt led to the spreading of its medical and therapeutical applications in Europe and, subsequently, in the United States. Its use in medicine decreased over the 20th century in the face of the appearance of other compounds of greater therapeutic effectiveness (AU)

Profesor Armando Roa y su aporte al estudio clínico de la marihuana en la perspectiva actual / Professor Armando Roa and his contribution to the clinical study of the marijuana in the present perspective

Se revisan los aspectos fundamentales del uso de la marihuana, a la luz del conocimiento actual, junto a los aspectos clínicos descritos por el Profesor Armando Roa sistematizados en su libro La Marihuana; se comenta sobre la importancia de su aporte a la clínica de este fenómeno